- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01173900
Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls
The aims of this study are:
- To determine feasibility of a school-based human papillomavirus (HPV) vaccination programme in Tanzania.
- To measure the uptake and acceptability of two different vaccination strategies in rural and urban schools.
- To examine the characteristics of accepters/refusers of vaccination and to identify reasons for acceptance, refusal or non-completion.
- To measure the cost of implementing a school-based HPV vaccination programme in Tanzania.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Vaccines against human papillomavirus infection, the primary cause of cervical cancer, are an attractive cervical cancer prevention strategy for resource poor settings which lack the infrastructure for establishing and maintaining complex screening programmes.Feasibility and costs of setting up and sustaining an HPV vaccination programme will depend on whether it can be added onto an existing health programme within schools, if one exists, or whether it has to be established as a separate health intervention. Other factors will also affect vaccine coverage. For example, uptake and overall effectiveness will be critically dependent on parental and community acceptability of a vaccine that prevents a sexually transmitted infection and how the vaccine is promoted and delivered by health-care providers will influence its uptake and acceptability.
This study will determine feasibility, uptake and acceptability of different delivery strategies of school-based HPV vaccination in Tanzania, examine factors related to acceptance or refusal of vaccination and measure the cost of implementing a school-based HPV vaccination programme in Tanzania.
Three doses of quadrivalent human papillomavirus (HPV) vaccine, (Gardasil®; Merck & Co) given at 0, 2 and 6 months, will be provided to 5000 primary school girls at 134 randomly selected schools in Mwanza Region in Tanzania. Selected schools will be randomly assigned to one of two delivery strategies (age-based or class-based) and coverage and acceptability of these vaccine delivery strategies will be compared. Qualitative research will be conducted before, during and after vaccination to examine barriers to vaccination and reasons for failure to complete vaccination as well as general community perceptions. To determine factors associated with refusal a case control study will be conducted on a 1:1 sample of 350 vaccine refusers and 350 accepters. The costs of introducing and scaling up HPV vaccines in schools will be estimated using established costing methods.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
-
Mwanza, Tanzania
- National Institute for Medical Research
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- female pupil
- attends selected school
- born in 1998 if enrolled in school selected for age-based delivery
- attending standard (class) 6 if enrolled in school selected for class-based delivery
Exclusion Criteria:
- has not previously received HPV vaccine
- has not participated in previous HPV vaccine trials
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Altro: Class-based delivery
All girls attending standard 6 in schools selected for class-based vaccine delivery
|
0.5 ml given at 0, 2, 6 months
|
Altro: Age-based delivery
All girls born in 1998 attending schools selected for age-based delivery
|
0.5 ml given at 0, 2, 6 months
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Vaccine coverage by delivery strategy
Lasso di tempo: Month 12
|
Vaccine coverage will be estimated for each dose given and for those completing the full course of vaccination and compared by delivery strategy.
|
Month 12
|
Vaccine coverage (dose 2) by delivery strategy
Lasso di tempo: Month 5
|
Month 5
|
|
Vaccine coverage (dose 1) by delivery strategy
Lasso di tempo: Month 3
|
Month 3
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Factors associated with refusal to vaccinate or to complete vaccination course
Lasso di tempo: Month 12
|
A case control study to determine factors associated with refusal will be conducted on a 1:1 sample of 350 vaccine refusers and 350 accepters.
|
Month 12
|
Identification of barriers to HPV vaccination
Lasso di tempo: Month 14
|
Qualitative research will be conducted to examine barriers to vaccination and reasons for failure to complete vaccination.
|
Month 14
|
Estimation of the costs of introducing and scaling up HPV vaccines in schools
Lasso di tempo: Month 10
|
Full financial and economic costs from the provider's perspective will be collected for the intervention.
Total costs of a district vaccination programme and cost per urban school and rural school reached (if urban/rural differences are identified) and cost per fully-vaccinated girl will be estimated for the two alternative delivery strategies.
|
Month 10
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Richard J Hayes, DSC, London School of Hygiene and Tropical Medicine
- Investigatore principale: Deborah :L Watson-Jones, MD, PhD, London School of Hygiene and Tropical Medicine
- Investigatore principale: John Changalucha, BSc, National Institute for Medical Research
Pubblicazioni e link utili
Pubblicazioni generali
- Quentin W, Terris-Prestholt F, Changalucha J, Soteli S, Edmunds WJ, Hutubessy R, Ross DA, Kapiga S, Hayes R, Watson-Jones D. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania. BMC Med. 2012 Nov 13;10:137. doi: 10.1186/1741-7015-10-137.
- Watson-Jones D, Baisley K, Ponsiano R, Lemme F, Remes P, Ross D, Kapiga S, Mayaud P, de Sanjose S, Wight D, Changalucha J, Hayes R. Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. J Infect Dis. 2012 Sep 1;206(5):678-86. doi: 10.1093/infdis/jis407. Epub 2012 Jun 18.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- MITU-001
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro cervicale
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
Zagazig UniversityNon ancora reclutamentoCervical IO Plasty nella gestione della placenta previa
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Canada, Stati Uniti, Singapore
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
Prove cliniche su Gardasil® HPV vaccine
-
Partha BasuAll India Institute of Medical Sciences, New Delhi; Tata Memorial Centre; Deutsches... e altri collaboratoriAttivo, non reclutanteCancro cervicale | Lesioni precancerose cervicaliIndia
-
Shanghai Zerun Biotechnology Co.,LtdWalvax Biotechnology Co., Ltd.Attivo, non reclutanteCancro cervicale | Infezioni da papillomavirus | CIN | Verruca genitale | VINCina
-
London School of Hygiene and Tropical MedicineMwanza Intervention Trials Unit, National Institute for Medical Research; York... e altri collaboratoriAttivo, non reclutanteInfezione da HPV | Malattia prevenibile con il vaccinoTanzania
-
University of British ColumbiaCompletato
-
Shanghai Bovax Biotechnology Co., Ltd.Chongqing Bovax Biopharmaceutical Co., Ltd.CompletatoCancro cervicale | Cancro vulvare | Cancro vaginale | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Verruca genitale | VIN 1 | VIN 2 | VIN 3 | AISCina
-
JhpiegoMerck Sharp & Dohme LLCCompletatoCancro cervicaleFilippine, Tailandia
-
University Hospital, BordeauxSconosciutoLupus eritematoso sistemico | Trapianto | Malattia immunitaria sistemicaFrancia
-
Boston Children's HospitalMerck Sharp & Dohme LLC; Harvard School of Public Health (HSPH)CompletatoMalattia infiammatoria intestinaleStati Uniti
-
Murdoch Childrens Research InstituteBrockhoff Foundation Australia; Shepherd Foundation AustraliaCompletato
-
Simon DobsonMinistry of Health, British ColumbiaCompletatoCancro cervicale | Verruche genitaliCanada